Introduction {#Sec1}
============

Mood disorders, either unipolar (MDD) or bipolar (BD), are common and disabling conditions, with relevant consequences at the individual and social level \[[@CR1]\]. To date, several drugs are available for the treatment of depressive and manic phases, but their effectiveness is limited and subject to wide interindividual variability. Only one-third of patients gain benefit from first antidepressant treatment in clinical settings \[[@CR2]\], and half of the patients with BD relapse within 2 years of treatment \[[@CR3]\]. This is also because the etiopathogenic factors leading to the risk to develop mood disorders are not yet understood.

Several studies have investigated the possible involvement of heritable factors, and therefore the variations at the level of single or multiple genes, both in disease risk and the interindividual variability in response to pharmacological treatments \[[@CR4]--[@CR9]\]. However, to date, no definite results have been obtained, since individual genes explain only small and partial effects of complex phenotypes \[[@CR10]\]. There is indeed much evidence in the literature of stronger and/or more selective genetic associations with disease-associated features or component phenotypes (e.g., a deep phenotyping approach \[[@CR11]\]) than with a main complex phenotype (e.g., diagnosis). Studies aimed at component phenotypes and their biological basis could therefore be promising for a better understanding of genetic effects \[[@CR11]\].

However, the several studies conducted so far have identified certain genes as possibly associated with mood disorders, response to psychotropic drugs and disease-associated features. These candidate genes are mainly involved in (but not limited to) monoaminergic neurotransmission, neuroplasticity and circadian rhythm pathways \[[@CR12]--[@CR14]\]. Mechanisms of signal transduction, transcription factors and pathways related to cellular metabolism have also been associated with mood disorder risk and response variability to pharmacological treatments \[[@CR15]--[@CR19]\].

Several genes are involved in neuroplasticity and neurotransmission pathways. Among these, brain-derived neurotrophic factor (*BDNF*) is a recognized regulator of synaptic function, with structural and functional effects \[[@CR20]\]. Cell adhesion molecule L1-like (*CHL1*) product guides migrating cells and growing neurites during development and learning in adulthood \[[@CR21]\]. Sialyltranferase X (ST8SIA2) is involved in the regulation of the adhesive properties of the neuronal cell adhesion molecule \[[@CR22]\]. Among genes related to neurotransmission, Serotonin receptor 2A (*HTR2A*) and Catechol-*O*-methyltransferase (*COMT*) are known key factors involved in neurotransmission, psychiatric disorders and the mechanism of action of several psychotropic drugs \[[@CR23], [@CR24]\]. Homer 1 protein (*HOMER 1*) belongs to a family of scaffolding proteins interacting with various post-synaptic density (PSD) proteins, where multiple neurotransmitter converge \[[@CR25]\]. Related Orphan Receptor A (*RORA*) plays a role in several physiological processes including circadian rhythm, with consistent evidence of involvement in mood disorders \[[@CR26]\].

In a previous study \[[@CR27]\], we investigated a set of 14 candidate genes involved in neuroplasticity, monoamine, circadian rhythm and transcription factor pathways as potentially related to individual responses to antidepressant treatment in MDD patients of Caucasian ancestry. We found that some genes involved in synaptic plasticity, neural activity and connectivity (*CREB1*, *ZNF804A* and *CHL1*), might be associated with an antidepressant response. In the present study, we investigated a set of 19 genes involved in the same pathways (neuroplasticity, monoamine, circadian rhythm, and transcription factor pathways) in a sample of Asian ethnicity (Korean), including both MDD and BD patients. Twelve of the genes investigated here were the same as tested on the European sample \[[@CR27]\] (see genetic analysis for details).

In the present study, we hypothesized that the genes we previously found associated with responses to antidepressant treatment in our Caucasian sample might also influence the response to treatments for mood disorders in Asian subjects, treated with both antidepressants and antimanic agents. The genes were originally selected based on their involvement either in the risk of disease, the response to treatment or other associated characteristics, as reported in previous literature. Therefore, in secondary analyses, we also hypothesized a possible involvement of these genes in the risk of developing the disease and as affecting some of the disease variables that we systematically collected (age of onset, lifetime history of suicide attempts, psychotic BD).

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

The samples considered for primary analysis in this study were comprised of 242 patients diagnosed with MDD and 132 patients diagnosed with BD according to the Diagnostic and Statistical Manual of Mental Disorders IV criteria \[[@CR28]\] consecutively admitted to the Department of Psychiatry of Seoul St. Mary's Hospital for pharmacological treatment. A total of 326 controls were also collected at the same site. Controls were consecutively collected among hospital staff and non-psychiatric hospital patients, who did not satisfy criteria for current or past psychiatric disorder. Non-psychiatric subjects suffering from moderate-severe, unstable medical or neurological conditions potentially affecting their psychological status and psychiatric evaluations were systematically excluded from the control sample. Recruitment details and exclusion criteria for patients have been previously described \[[@CR29], [@CR30]\]. Briefly, all patients had to be eligible for pharmacological treatment. MDD patients had to satisfy criteria for a current episode of MDD requiring treatment with antidepressants, while BD patients had to satisfy criteria for a current manic/mixed episode requiring treatment with mood stabilizers (for assessing antimanic effects with mood stabilizers (e.g., \[[@CR29], [@CR31]--[@CR34]\]). Patients were all undergoing naturalistic treatments with venlafaxine or paroxetine (MDD), lithium, valproate, carbamazepine and lamotrigine (BD). The choice of treatment was taken by the clinician based on international guidelines. Due to intent prior to the present study, only MDD patients treated with venlafaxine and paroxetine were included in this sample. A severe or unstable medical and/or neurological conditions, treatment with a long-acting antipsychotic, current or recent (past 6 months) comorbidity for alcohol/substance use disorder represented exclusion criteria. All the subjects were Koreans, of Korean ancestry.

The local ethical committee approved the study procedures, and all the subjects were included after they had signed an informed consent. Socio-demographic and clinical features of the samples are reported in Table [1](#Tab1){ref-type="table"}. Case and controls were not different in terms of sex distribution (*p* = 0.39) and only marginally in terms of age (*p* = 0.08).Table 1Socio-demographic and clinical dataMDD sample\
*n* = 242 (34.6%)BD sample\
*n* = 132 (18.9%)Healthy controls\
*n* = 326 (46.6%)Statistical details*n*(%)*n*(%)*n* (%)Sex Male92 (38.02%)87 (65.91%)147 (45.09%)*p* \< 0.001 Female150 (61.98%)45 (34.09%)179 (54.91%)Family history of psychiatric disorders No194 (80.17%)37 (28.03%)--*p* \< 0.001 Yes47 (19.42%)46 (34.85%) Missing1 (0.41%)49 (37.12%)Suicide attempt history No187 (77.27%)89 (67.42%)--BD = MDD\
*p* = 0.5840 Yes54 (22.31%)22 (16.67%) Missing1 (0.41%)21 (15.91%)Psychotic BD No--57 (43.18%)---- Yes73 (55.30%) Missing2 (1.52%)MDD sample\
*n* = 242 (34.6%)BD sample\
*n* = 132 (18.9%)Healthy controls\
*n* = 326 (46.6%)Statistical detailsMean ± SDMean ± SDMean ± SDAge43.57 ± 14.8136.36 ± 11.6145.36 ± 13.07*p* \< 0.001Age at onset39.75 ± 13.7626.58 ± 10.20--BD \< MDD\
*p* \< 0.001Hamilton Depression Rating Scale (baseline)22.75 ± 7.307.70 ± 4.03--BD \< MDD\
*p* \< 0.001Young Mania Rating Scale (baseline)--33.27 ± 9.09----

Assessment {#Sec4}
----------

Patients and controls were evaluated for psychiatric disorders by the Mini-International Neuropsychiatric Interview \[[@CR28]\]. Demographic and clinical variables, including family history for psychiatric disease, age at first illness episode (onset) and history of suicide attempt, were systematically collected by clinical interviews and review of clinical charts. In BD patients, the presence of psychotic features was also systematically collected. Depressive symptoms severity was evaluated by the Hamilton Depression Rating Scale (HDRS) \[[@CR35]\] in both MDD and BD patients. Manic symptoms (BD patients only) were evaluated by the Young Mania Rating scale (YMRS) \[[@CR36]\].

Response to antidepressant treatment, remission and resistance to treatments (primary outcomes) were defined according to Schosser et al. \[[@CR37]\]. Briefly, response to treatment is defined as a ≥ 50% improvement of HDRS scores from baseline to endpoint; remission as a HDRS score of ≤ 7 at the endpoint; and resistance as non-response to at least two adequate consecutive antidepressant trials (including the present one) \[[@CR37]\]. The efficacy of mood stabilizers was evaluated in terms of response, defined as a ≥ 50% improvement of YMRS scores from baseline to endpoint, and remission defined as YMRS total score ≤ 12 \[[@CR36]\].

Genetic Analyses {#Sec5}
----------------

Genetic single nucleotide polymorphisms (SNPs) were chosen as previously described \[[@CR27]\], but in the context of the Asian population. Briefly, SNPs were selected based on (1) a reported prevalence of at least 5% for the variant allele among the Asian population according to <http://hapmap.ncbi.nlm.nih.gov>; (2) tagging approach \[complete linkage disequilibrium (R2 ≥ 0.08) with one or more neighbor SNPs\]; (and 3) availability of a validated assay.

High-throughput genotyping using a pyrosequencer (Biotage, Sweden) was used to genotype the genomic desossiribonucleic acid (DNA) from blood. Polymerase chain reaction primers (Bioneer, Daejeon, Korea) and sequencing primers (Bioneer) used for the pyrosequencing assay were designed through Pyrosequencing Assay Design Software v.1 (Biotage), and 1 primer of each primer set was biotinylated. A total of 141 SNPs within 19 genes were initially genotyped for this study. After pruning according to genotyping rate and minor allele frequency (MAF) within the sample under investigation, 132 SNPs remained. Three SNPs were excluded since they were not in Hardy--Weinberg equilibrium (HWE) (PLA2G4A rs10737276, NCAPG2-ESYT2 rs12668837 and RORA rs1403737), leaving 129 SNPs (details in Table [2](#Tab2){ref-type="table"}).Table 2SNPs investigatedChrGeneNo. of SNPs; valid (total)SNPs1PLA2G4A5 (6)**rs10489407, rs6695515, rs10798069,** *rs10737276,* **rs12144159, rs7414079**2CREB12 (4)*rs889895,* **rs6740584,** *rs2551922,* **rs2254137**3CHL18 (10)**rs1516338, rs1516340, rs4003413, rs17271940,** *rs17274531, rs9990005,* **rs331893, rs2272522, rs13078884, rs9841789**3GSK3B4 (5)**rs2037547, rs2873950, rs1719895, rs6782799,** *rs1381841*5HOMER18 (8)**rs3822568, rs6872497, rs4455546, rs12657371, rs12514775, rs6893883, rs4132033, rs10042665**7SP45 (5)**rs2282888, rs2237304, rs10272006, rs12673091, rs9648275**7NCAPG24 (4)**rs10772, rs877279, rs12113120, rs4621754**7NCAPG2-ESYT2^a^2 (3)*rs12668837,* **rs9801117, rs6459896**7ESYT26 (6)**rs2013, rs3763406, rs3816462, rs2788469, rs842446, rs13233513**7ESYT2-WDR60^a^2 (2)**rs1039621, rs2657375**7WDR606 (6)**rs2657323, rs1188974, rs2788478, rs10275341, rs2527204, rs2657340**7VIPR22 (2)**rs3793222, rs2270313**8PPP3CC4 (4)**rs1522248, rs10108011, rs7430, rs2249098**9SIGMAR11 (2)*rs12115673,* **rs10814130**11BDNF7 (7)**rs1519480, rs7124442, rs6265, rs11030101, rs11030102, rs11030104, rs12273363**13HTR2A11 (12)**rs7323441,** *rs6314,* **rs7997012, rs1923886, rs643627, rs2224721, rs582385, rs17288723, rs2296973, rs6313, rs6311, rs1328685**15RORA26 (27)**rs10438338, rs7167685, rs1657792, rs8040067, rs11630262, rs339996, rs9806453, rs2553235, rs1020729, rs1871858, rs12900122, rs17204440, rs12913922, rs341382, rs1673319, rs8041466, rs1234805, rs12148149, rs11071570, rs4775340, rs2414687, rs7178442,** *rs1403737,* **rs17270745, rs809736, rs7177611, rs10519113**15ST8SIA211 (12)**rs3759917, rs2305561, rs3784723, rs3784722, rs4777989, rs11629679, rs7168443, rs2290492, rs8035760, rs11853992,** *rs17522085,* **rs2279447**21S100B7 (8)*rs9983498,* **rs2839350, rs9722, rs2186358, rs2839364, rs2839365, rs3788266, rs2839366**22TXNRD22 (2)**rs4646310, rs2020917**22COMT6 (6)**rs933271, rs5993883, rs740603, rs2239393, rs4680, rs174696**All the SNPs genotyped in the Korean sample are reported in this table. Valid SNPs are shown in bold; those that were excluded from the analyses in italics (for details see "[Methods](#Sec2){ref-type="sec"}" section)^a^SNPs in these rows were located between two genes and, according to NCBI SNP database (<https://www.ncbi.nlm.nih.gov/snp/>), may affect both

Of the 19 genes analyzed, 12 (*PLA2G4A*,*CREB1*,*CHL1*,*GSK3B*,*SP4*,*VIPR2*,*PPP3CC*,*BDNF*,*HTR2A*,*RORA*,*ST8SIA2* and*COMT*) were previously analyzed in our Caucasian sample \[[@CR27]\]. Two genes analyzed in Caucasians (*MAPK1* and *ZNF804A*) were excluded from the analysis as previously independently analyzed in these samples \[[@CR30], [@CR38]\]. Other 7 new genes were also analyzed: *HOMER1*,*NCAPG2*,*ESYT2*,*WDR60*,*SIGMAR1*,*S100B* and *TXNRD2*.

Statistical Analysis {#Sec6}
--------------------

The HWE of alleles and the linkage disequilibrium (LD) among SNPs were analyzed using the Haploview software (v.3.2) for Windows \[[@CR39]\]. Main statistical analyses were performed using the IBM SPSS package for windows (<http://www.ibm.com/analytics/us/en/technology/spss/>). Single SNPs associations were tested by the Chi square test, logistic regression models when controlling for potential confounding factors, one-way analysis of variance/covariance or corresponding non-parametric tests. The statistical package "haplo.score" (R-project, <http://cran.r-project.org/>) was employed to compute block of alleles in LD (haplotypes) and test their association with the outcome variables.

The primary outcomes were represented by treatment effects in terms of response to antidepressant or mood stabilizers, remission and resistance to antidepressants. In secondary analyses, we tested genetic effects on disease risk (cases vs. controls) and disease-associated features (age of onset, history of suicide attempt, psychotic BD). The effect of potentially confounding factors was systematically checked, including age, sex and type of drug administered. Baseline symptoms severity (baseline HDRS and YMS scores) was used as a covariate when analyzing remission (not when analyzing response because it includes baseline severity by definition).

To limit the risk of false positives due to multiple testing, a Bonferroni correction was applied \[[@CR40]\]. The corrected alpha-value was calculated dividing 0.05 for the number of genes analyzed (0.05/19 = 0.0026). Power estimation was calculated through G\*Power v.3.1.9.2 \[[@CR41]\]. Considering a MAF of 0.30, we had a sufficient power of 0.80 to detect odds ratios (OR) of 1.89 for the BD subsample and of 1.77 for the MDD subsample.

Compliance with Ethics Guidelines {#Sec7}
---------------------------------

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. All the patients were informed in detail about the aims and the procedures of the study, and they signed an informed consent prior to inclusion into the study. The protocol and the informed consent were approved by the local ethical committee (approval number HC10TISI0031).

Results {#Sec8}
=======

HWE test details are reported in supplementary Table 1.

Genetic Effects on Treatment Efficacy {#Sec9}
-------------------------------------

Single SNPs were not significantly associated with response, remission with or resistance to antidepressant treatment in MDD, and neither were they significantly associated with response to or remission with mood stabilizers treatment in BD patients. However, some trends were observed. In MDD, *BDNF*(rs1103010, *p* = 0.006; rs11030104, *p* = 0.028; rs6265, *p* = 0.017) and *HOMER1 (*rs10042665, *p* = 0.003; rs12514775. *p* = 0.011) showed trends of association with response; *RORA*(rs1020729, *p* = 0.025;, rs11071570, *p* = 0.003; rs12148149, *p* = 0.045; rs8041466, *p* = 0.040) and *HTR2A*(rs643627, *p* = 0.008) with remission; CHL1 (rs1516338, *p* = 0.008) with treatment resistance. Two *BDNF* variants (s1519480, *p* = 0.003; rs7124442, *p* = 0.004) also showed trends of association with response to mood stabilizers in BD, in both single SNP and haplotype analysis. Further details are reported in supplementary Table 1.

Secondary Outcomes {#Sec10}
------------------

Significant associations are reported in Table [3](#Tab3){ref-type="table"}.Table 3Significant genetic associationsGeneVariantFrequenciesStatistical detailsRaw *p* valueRisk ^(BD)^ CHL1rs4003413 (A/C)A = 334\
Not A = 123B = 0.727; SE = 0.240; OR = 2.068\|C.I. (1.292--3.309)0.0026 HTR2Ars643627 (A/G)G = 346\
Not G = 111B = 0.764; SE = 0.252; OR = 2.147\|C.I. (1.311--3.518)0.0025Age at onset ^(BD)^ RORArs1020729 (C/T)C = 83\
Not C = 39Mann--Whitney *U* testMean (SD): Not C = 22.5 (8.322)Mean (SD): C = 28.5 (10.473)0.0020History of suicide attempt ^(MDD)^ HOMER1rs6872497 (A/G)A = 54\
Not A = 186B = 1.918; SE = 0.622; OR = 6.805\|C.I. (2.012--23.010)0.0001GeneVariantFrequenciesStatistical details*p* valueSim-*p*valueHaplo-frequencyHaplo-scoreHaplotype (rs6872497--rs3822568) A--C0.12− 3.250.0010**0.0010** G--C0.560.200.83800.8400 G--T0.322.160.03100.0290Psychotic BD RORArs11630262 (A/G)A = 21\
Not A = 109Not A vs. A: B = 1.669; SE = 0.549; OR = 5.307\|C.I. (1.809--15.572)**0.0009**See Online Appendix 1 for full name of genes. Bold type indicates significance*MDD* major depressive disorder, *BD* bipolar disorder

### Disease risk {#Sec15}

Two variants were found significantly associated with BD risk in case--control comparison: *CHL1* rs4003413 and *HTR2A* rs643627 (Table [3](#Tab3){ref-type="table"}). Four other SNPs in these genes (*CHL1* rs1516338, *p* = 0.029 and rs2272522, *p* = 0.033; HTR2A rs643627, *p* = 0.034 and rs7997012, *p* = 0.028) also showed trends of association with BD risk. A number of other genetic variants showed trends of association with BD risk, especially *ST8SIA2* (rs11629679, rs3759917, rs3784723, rs4777989, rs8035760), *RORA* (rs10438338, rs12913922, rs17204440), *BDNF*(rs11030104, rs6265)*, GSK3B*(rs1719895, rs2037547). Further details are reported in supplementary Table 2. No genetic variant was associated with MDD risk in case--control analysis after Bonferroni correction. Only trends of association could be observed: *RORA*(rs10519113, rs12900122, rs8040067)*, CHL1* (rs1516340)*, COMT*(rs2239393)*, HTR2A*(rs2224721)*, SP4*(rs2237304) and *ST8SIA2*(rs11629679, rs3784723).

### Age at onset, suicide attempt, psychotic BD {#Sec16}

Young age at onset in BD was significantly associated with *RORA* rs1020729 (Table [3](#Tab3){ref-type="table"}). Interesting signals were also observed for age at onset, especially regarding *COMT* in BD (rs4680), but also *S100B* in MDD (rs2839365, rs3788266, rs9722), and *ST8SIA2* in both MDD (rs8035760) and BD (rs3759917). A variant in *HOMER1,* rs6872497, was significantly associated with history of previous suicide attempts in MDD subjects (Table [3](#Tab3){ref-type="table"}). In particular, this SNP was also associated with a history of suicide attempts in haplotype combination with rs3822568 (Table [3](#Tab3){ref-type="table"}). Other genes showed trends of association with suicide attempts in MDD subjects, especially variants located within and across *ESYT2* and *WDR60* (rs7997012, rs643627, rs1188974 and rs1188974-rs2788478 haplotype). Finally, a variant in *RORA* (rs11630262) also showed association with psychotic BD, along with two other nearly significant variations (rs11071570, rs2553235). Trends of association were also observed for *BDNF* and *COMT*. See supplementary Table 2 for further details.

Discussion {#Sec11}
==========

The genes we investigated regulate the functioning of systems that have been previously reported as consistently involved in the mechanisms of action of antidepressant drugs and mood stabilizers \[[@CR15]--[@CR19]\]. Despite this, none of the genetic variants was found significantly associated neither with antidepressant treatment in MDD, nor with mood stabilizers in BD. However, some trends of effect were observed for SNPs within *BDNF*,*HTR2A*,*RORA* and *CHL1*. The only data in line with the previous work on the Caucasian population \[[@CR27]\] concern the effect of *CHL1* (rs1516338) on resistance to antidepressant drugs. *CHL1* encodes for a neural recognition molecule, repeatedly implicated in antidepressant response \[[@CR13], [@CR42]--[@CR47]\]. The possible association of BDNF, HTR2A (Serotonin receptor 2A) and, to a lower extent, RORA with the antidepressant response, not supported in our previous work, was however indicated by previous analyses on other samples \[[@CR48], in which see refs: Bjorkholm, 2016 \#87; Hennings, 2015 \#73; Colle, 2015 \#89; Lin, 2014 \#20; Garriock, 2010 \#91\].

When investigating the association with disease risk, *CHL1*(rs4003413) and *HTR2A* (rs643627) were found to ne significantly associated with BD in case--control analysis, and with MDD as trends (other SNPs involved; see supplementary Table 2). These findings are in line with some previous evidence of the involvement of *CHL1* in BD \[[@CR49]\] and *HT2A* in both BD \[[@CR50], [@CR51]\] and MDD \[[@CR52]--[@CR55]\].

Two SNPs in *RORA* (rs1020729 and rs11630262) were associated with age at onset in BD and psychotic BD, respectively. Other SNPs in *RORA* showed trends of association with both MDD and BD risk, and antidepressant treatment outcome. *RORA* is critically involved in the regulation of circadian rhythms, which are known to be core features of Mood disorders and other psychiatric disorders \[[@CR56]--[@CR58]\]. They can also be involved in the occurrence of psychotic symptoms in BD \[[@CR59]\]. *RORA* was not previously implicated in BD \[[@CR60]\], but it can impact on depressive, manic and psychotic symptoms \[[@CR61]--[@CR63]\], efficacy of treatments for depression \[[@CR64]\], and treatment with lithium for BD \[[@CR65]\].

*HOMER1* was associated with suicide risk in MDD (rs6872497) and, as a trend, with antidepressant response (supplementary Table 1). *HOMER1,* implicated in stress response pathways \[[@CR66]\], was previously hypothesized as involved in suicidal features \[[@CR67], [@CR68]\]. Further, in BD, *HOMER1* has been shown to influence brain grey and white matter structure and function, long-term effects of lithium on white matter structure, and antidepressant response to chronotherapeutics, thus suggesting that glutamatergic neuroplasticity and Homer1 function might play a role in mood psychopathology and response to treatment \[[@CR69]\]. The region with interesting genes *ESYT2* and *WDR60* (Chr 7) also provided trends of association with suicidal behavior (supplementary Table 2). However, to our knowledge, there are no reports regarding an involvement of *ESYT2* or *WDR60* in suicidal behavior. *ESYT2* and WDR60 have both been implicated in neurodevelopmental pathways \[[@CR70]\].

Finally, interesting genes that may potentially influence multiple disease features were *ST8SIA2* and *COMT*. Regarding *COMT*, there is a rich literature about this gene and its implication in Mood disorders, being implicated in the metabolism of neurotransmitters \[[@CR71]--[@CR73]\]. Less evidence has been reported for *ST8SIA2*; its product modulates the adhesive properties of neural cell adhesion molecules, which mediate adhesion among neurons and between neurons and muscle. *ST8SIA2* seems to be involved in multiple psychiatric disorders \[[@CR74], [@CR75]\].

Strengths and Limitation {#Sec12}
------------------------

Strengths are represented by: focus on genes that previously received substantial evidence of involvement in mood disorders (*COMT*,*HTR2A*,*BDNF*,*CHL1*,*Homer1* in particular); analysis of multiple SNPs within each gene; reanalysis in Asians of a set of genes previously tested for antidepressant response in Caucasians \[[@CR27]\]; simultaneous evaluation of genetic effects on multiple disease phenotypes and critical associated features; and relatively large samples of affected subjects and healthy controls.

On the other hand, testing a large number of genetic variants on multiple phenotypes exponentially increases the risk of false positive results, especially on medium-sized samples. In some cases, the low allelic variability might decrease the power of the statistical analysis. However, we used a multiple testing correction that could be considered as overly conservative given the previous results. Further, we analyzed common SNPs only, but not other rare mutations or other polymorphic variants such as copy number variations or rare variants. Therefore, a complete coverage of the genes is not guaranteed. All recruited BD patients were in a manic or mixed phase. This made it possible to specifically evaluate the response to antimanic agents. On the other hand, it prevented the evaluation of antidepressant response in BD patients. Control subjects were recruited among hospital staff and patients. Although we checked for the absence of lifetime psychiatric conditions, as well as the absence of severe/unstable medical or neurological conditions in control hospital patients, we cannot ensure full representativeness of our control sample with a control sample drawn from the normal population. Moreover, controls were not systematically evaluated for family history of psychiatric disease. Both patients and controls were consecutively collected and not matched for age and gender. However, cases and controls resulted to be similar in terms of age and gender. Patients underwent a naturalistic treatment and were not randomized to one or another treatment arm. All MDD patients were treated with paroxetine or venlafaxine for purposes prior to this work. Patients with BD were also treated with different mood stabilizers. There is the possibility of a potential confounding effects of different compounds; however, this has not been commonly observed in the previous studies (e.g., \[[@CR76]\]). Furthermore, treatment outcomes were evaluated after the 6th and before the end of the 8th week of treatment in order to identify early predictors of response to treatments. However, this relatively short observation period may have led to an overestimation of the rates of non-response and treatment resistance. When focusing on component phenotypes (disease-associated features), we systematically collected only age at onset, suicidal behavior and psychotic BD. Psychosis in MDD was not systematically collected. The evaluation of other relevant phenotypic aspects could have highlighted a greater number of genetic effects. Finally, we could only detect small genetic effects with moderately sufficient size (OR \> 2.00) only within secondary analyses in the BD sample (risk of illness, age of onset and psychotic BD) and history of attempted suicide in the MDD sample.

Conclusions {#Sec13}
===========

The present study was not able to identify major genetic effects on the response to pharmacological treatments for depression and manic/mixed episodes in two samples of Asian ethnicity. Marginal results confirmed previous evidence on antidepressant response for *CHL1, BDNF, HTR2A* and *RORA*, but none of sufficient magnitude to survive the statistical correction of significance. The analyses on secondary outcomes indicated a possible genetic modulatory effect on the risk of BD (*CHL1*,*HTR2A*) and a possible role of *RORA* in forms of BD characterized by early onset and psychotic symptoms. In MDD, *HOMER1* could influence suicidal features. Given the several limitations of the present study, the results obtained should be interpreted in the light of the broader scientific literature.
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